NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free PRPH Stock Alerts $5.33 +0.17 (+3.29%) (As of 05:18 PM ET) Add Compare Share Share Today's Range$4.93▼$5.4550-Day Range$4.61▼$7.3552-Week Range$4.05▼$9.94Volume135,601 shsAverage Volume45,994 shsMarket Capitalization$101.70 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProPhase Labs alerts: Email Address ProPhase Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.4% Upside$11.00 Price TargetShort InterestHealthy1.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to $0.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector598th out of 916 stocksPharmaceutical Preparations Industry275th out of 413 stocks 3.5 Analyst's Opinion Consensus RatingProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProPhase Labs has received no research coverage in the past 90 days.Read more about ProPhase Labs' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.88% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in ProPhase Labs has recently decreased by 3.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPH. Previous Next 2.0 News and Social Media Coverage News SentimentProPhase Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProPhase Labs this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.45% of the stock of ProPhase Labs is held by institutions.Read more about ProPhase Labs' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($0.82) to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ProPhase Labs' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ProPhase Labs Stock (NASDAQ:PRPH)ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More PRPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPH Stock News HeadlinesMay 21 at 3:22 AM | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Stock Crosses Above Two Hundred Day Moving Average of $5.08May 15, 2024 | seekingalpha.comProPhase Labs: Hidden Gem With An AI KickerMay 15, 2024 | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Lifted to Sell at StockNews.comMay 9, 2024 | globenewswire.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - UpdatedMay 9, 2024 | finance.yahoo.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.May 2, 2024 | finance.yahoo.comPROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9May 2, 2024 | finance.yahoo.comPROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9April 25, 2024 | globenewswire.comProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 16, 2024 | marketwatch.comProPhase Labs Shares Jump on New AI-Based ProjectApril 16, 2024 | globenewswire.comProPhase Labs Unveils Project ZenQ-AIApril 10, 2024 | finanznachrichten.deProPhase Labs, Inc.: ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024April 10, 2024 | baystreet.caProPhase Flat on Cancer Drug ProgressApril 10, 2024 | globenewswire.comProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024April 1, 2024 | globenewswire.comProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | finance.yahoo.comProPhase Labs, Inc. (PRPH)March 18, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | msn.comPRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023March 15, 2024 | globenewswire.comProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic InitiativesMarch 14, 2024 | benzinga.comProPhase Labs's Earnings: A PreviewMarch 12, 2024 | msn.comDown 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%March 8, 2024 | globenewswire.comPROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024March 1, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value EstimateFebruary 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)February 21, 2024 | finance.yahoo.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 20, 2024 | finance.yahoo.comProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMARTSee More Headlines Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/23/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees113Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+117.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,780,000.00 Net Margins-82.18% Pretax Margin-112.12% Return on Equity-44.96% Return on Assets-25.88% Debt Debt-to-Equity Ratio0.31 Current Ratio1.88 Quick Ratio1.73 Sales & Book Value Annual Sales$44.38 million Price / Sales2.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book2.16Miscellaneous Outstanding Shares19,080,000Free Float15,130,000Market Cap$96.74 million OptionableOptionable Beta-0.17 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Ted William Karkus (Age 65)Chairman & CEO Comp: $902.2kMr. Jed A. Latkin (Age 50)Chief Operating Officer & Head of Finance Department Mr. Sergio MirallesExecutive VP & Chief Information OfficerKey CompetitorsLeap TherapeuticsNASDAQ:LPTXEnzo BiochemNYSE:ENZQ32 BioNASDAQ:QTTBVivani MedicalNASDAQ:VANIRelmada TherapeuticsNASDAQ:RLMDView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 9,416 shares on 5/10/2024Ownership: 3.429%View All Institutional Transactions PRPH Stock Analysis - Frequently Asked Questions Should I buy or sell ProPhase Labs stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRPH shares. View PRPH analyst ratings or view top-rated stocks. What is ProPhase Labs' stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for ProPhase Labs' stock. Their PRPH share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 106.4% from the stock's current price. View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts. How have PRPH shares performed in 2024? ProPhase Labs' stock was trading at $4.52 on January 1st, 2024. Since then, PRPH shares have increased by 17.9% and is now trading at $5.33. View the best growth stocks for 2024 here. When is ProPhase Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our PRPH earnings forecast. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.21. The business earned $3.63 million during the quarter, compared to analysts' expectations of $9.86 million. ProPhase Labs had a negative net margin of 82.18% and a negative trailing twelve-month return on equity of 44.96%. During the same period last year, the company earned $0.03 earnings per share. What is Ted Karkus' approval rating as ProPhase Labs' CEO? 2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH). Who are ProPhase Labs' major shareholders? ProPhase Labs' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.43%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRPH) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsThis military-backed stock “owns” AI marketPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
